Moreover, there is no assay to measure biologically relevant YAP activity in a certain patient, and thus there is, to date, no biomarker that will predict for clinical relevance of YAP overexpression in patients with PCa. This evidence concerns the gene YAP1 and posterior cortical atrophy.